Company News Summary
Mayne Pharma Group Launches Fabior and Sorilux in the US
Original announcement: Mayne Pharma launches Fabior and Sorilux in the US
Mayne Pharma Group announced the commencement of promotion of Fabior (tazarotene) Foam, 0.1% and Sorilux (calcipotriene) Foam, 0.005% in the US by the Company'S Specialty Brands division. These foam products previously marketed by GlaxoSmithKline (GSK), were acquired by the Company in August 2016 and are complementary dermatology products to Doryx, the first branded product launched by the Company's Specialty Brands division in the US in May 2015. Fabior is a patent-protected foam product indicated for the topical treatment of acne, the most prevalent skin disease in the US affecting as many as 50M people of all ages.
See more ASX300 News Announcements